Monotherapy versus combined androgen blockade in patients with advanced prostate cancer.
作者信息
Errejon Abelardo, Crawford E David
出版信息
Cancer. 2002 Jul 15;95(2):209-10. doi: 10.1002/cncr.10648.
PMID:12124816
Abstract
摘要
相似文献
1
Monotherapy versus combined androgen blockade in patients with advanced prostate cancer.
Cancer. 2002 Jul 15;95(2):209-10. doi: 10.1002/cncr.10648.
2
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
BJU Int. 2004 Jun;93(9):1177-82. doi: 10.1111/j.1464-410x.2004.04803.x.
3
Hormonal therapy for prostate cancer: past, present and future.
Expert Rev Anticancer Ther. 2002 Feb;2(1):37-47. doi: 10.1586/14737140.2.1.37.
4
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.
5
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Cancer. 2009 Aug 1;115(15):3376-8. doi: 10.1002/cncr.24393.
6
Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
J Urol. 2004 Aug;172(2):774; author reply 774-5. doi: 10.1097/01.ju.0000132508.20023.08.
7
[Early versus late hormonal treatment in advanced prostate cancer].
Actas Urol Esp. 1999 Jul-Aug;23(7):557-64.
8
Managing prostate cancer: the role of hormone therapy.
Can J Urol. 2007 Dec;14 Suppl 1:10-8.
9
Endocrine treatment of prostate cancer.
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
10
Advanced prostate cancer. Hormonal treatment.
Tunis Med. 2005 Dec;83 Suppl 12:71-3.
Zotero 插件